International Journal of Cancer Management

Published by: Kowsar

Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma

Reza Ghanbari 1 , 2 , Neda Mosakhani 3 , Jahanbakhsh Asadi 4 , * , Nazila Nouraee 5 , Seyed Javad Mowla 5 , Yaghoub Yazdani 6 , Ashraf Mohamadkhani 2 , Hossein Poustchi 2 , Sakari Knuutila 3 and Reza Malekzadeh 2
Authors Information
1 Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, IR Iran
2 Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Pathology, Haartman Institute, Helsinki University, Helsinki, Finland
4 Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
5 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Moddares University, Tehran, IR Iran
6 Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: May 28, 2015, 8 (3); e2329
  • Published Online: May 22, 2015
  • Article Type: Research Article
  • Received: October 21, 2014
  • Revised: November 5, 2014
  • Accepted: November 12, 2014
  • DOI: 10.17795/ijcp2329

To Cite: Ghanbari R, Mosakhani N, Asadi J, Nouraee N, Mowla S J, et al. Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma, Int J Cancer Manag. 2015 ; 8(3):e2329. doi: 10.17795/ijcp2329.

Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225-49[DOI][PubMed]
  • 2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5): 277-300[DOI][PubMed]
  • 3. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6): 1541-9[DOI][PubMed]
  • 4. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366(25): 2345-57[DOI][PubMed]
  • 5. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8): 687-96[DOI][PubMed]
  • 6. Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012; 7(11)[DOI][PubMed]
  • 7. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012; 59(4): 467-74[PubMed]
  • 8. Bhardwaj A, Singh S, Singh AP. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2010; 2(5): 213-9[DOI][PubMed]
  • 9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2): 215-33[DOI][PubMed]
  • 10. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009; 174(4): 1131-8[DOI][PubMed]
  • 11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30): 10513-8[DOI][PubMed]
  • 12. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009; 89(5): 597-606[DOI][PubMed]
  • 13. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54(3): 482-90[DOI][PubMed]
  • 14. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5): 672-5[DOI][PubMed]
  • 15. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14(9): 2588-92[DOI][PubMed]
  • 16. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654-9[DOI][PubMed]
  • 17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11): 857-66[DOI][PubMed]
  • 18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17): 1793-801[DOI][PubMed]
  • 19. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4): 425-36[DOI][PubMed]
  • 20. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, et al. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights. 2006; 2: 113-21[PubMed]
  • 21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043): 834-8[DOI][PubMed]
  • 22. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010; 79(6): 817-24[DOI][PubMed]
  • 23. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B. Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol. 2013; 30(1): 373[DOI][PubMed]
  • 24. Valencia K, Martin-Fernandez M, Zandueta C, Ormazabal C, Martinez-Canarias S, Bandres E, et al. miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone. 2013; 52(1): 532-9[DOI][PubMed]
  • 25. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009; 284(37): 24696-704[DOI][PubMed]
  • 26. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003; 89(5): 899-906[DOI][PubMed]
  • 27. Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014; 116(1): 67-75[DOI][PubMed]
  • 28. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014; 13: 92[DOI][PubMed]
  • 29. Shen WW, Zeng Z, Zhu WX, Fu GH. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl). 2013; 91(8): 989-1000[DOI][PubMed]
  • 30. Zhou JL, Jiang Z, Wang ZW, Zou ST, Zhang YX, Cai W, et al. MicroRNA-142-3p is frequently upregulated in colorectal cancer and may be involved in the regulation of cell proliferation. Chin Sci Bull. 2013; 58(23): 2836-45[DOI]
  • 31. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012; 72(6): 1504-17[DOI][PubMed]
  • 32. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008; 112(10): 4202-12[DOI][PubMed]
  • 33. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011; 71(1): 225-33[DOI][PubMed]
  • 34. Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, et al. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013; 133(5): 1286-93[DOI][PubMed]
  • 35. Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 2012; 205(3): 113-23[DOI][PubMed]
  • 36. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011; 32(1): 2-9[DOI][PubMed]
  • 37. Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014; 3(6): 1544-52[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments